Key Points Systemic Light Chain Amyloidosis Immunoglobulin light chain (AL) amyloidosis
is a rare disease that occurs when a plasma cell disorder produces monoclonal light chains …

In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell
clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the …

The systemic amyloidoses are a broad spectrum of diseases that result from misfolding of
proteins that aggregate into b-sheet amyloid fibrils. Over 35 amyloidogenic precursor …

Background Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by
deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells …

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Systemic amyloidosis is a rare protein misfolding and deposition disorder leading to
progressive organ failure. There are over 15 types of systemic amyloidosis, each caused by …

Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide,
bortezomib, and dexamethasone (CyBorD) is considered standard of care. Based on …

PURPOSE Oral melphalan and dexamethasone (MDex) were considered a standard of care
in light-chain (AL) amyloidosis. In the past decade, bortezomib has been increasingly used …

Often considered a rare disease, cardiac amyloidosis is increasingly recognized by
practicing clinicians. The increased rate of diagnosis is in part due the aging of the …